$Invesco QQQ(QQQ)$ Hard to understand being unimpressed with a company whose Q3 revenue exceeded Q1 and Q2 combined. Some people just seem miserable for the sake of it.
$ImmunityBio, Inc.(IBRX)$ $Invesco QQQ(QQQ)$ $SPDR S&P 500 ETF Trust(SPY)$ IBRX Anktiva was approved for a bladder cancer indication last week that triples their patient potential. Almost immediately a big pharma writer at Stat News came out with negative coverage, even though the data was better and adverse events were lower than Merck's Keytruda. Analysts have raised or reiterated price targets. Then today more unknown writers showed up with negative takes. After an early 5% gain, shorts attacked the bids and it closed down 1.20. Short interest was 34% this morning, trapped unless they used illegal tactics to sow doubt. This kind of attack slow
$SPDR S&P 500 ETF Trust(SPY)$ $Invesco QQQ(QQQ)$ I'm closing out my short positions. The market looks set to rally into the close, and I'd wager we see a multi-day uptrend. October and November heading into midterms do tend to run positive.
$Invesco QQQ(QQQ)$ Greetings from Dubai. Monday's trading. Special Intelligence Report. We anticipate Operation Final Flush being implemented within the first hours of trading Monday, to flush out the final stage of weak hand investors. We anticipate QQQ to reach 695 then 683, but we do not anticipate a flush to 665 as most US news media headlines reporting that would mimic the 1987 crash style over the weekend. We urge US retail investors to be prepared and act accordingly. We expect QQQ to recover this Final Operation Flush by Tuesday and be ready for an earnings season rally back to 722 then to 742. We maintain price target 786-797 by end of Oct. and potential huge yearend rally to 947-978. Meanwhile, tread c